GILEAD SCIENCES 2026GILEAD SCIENCES 2026GILEAD SCIENCES 2026

GILEAD SCIENCES 2026

No trades
See on Supercharts

US375558BF9 analysis



Key facts


Issue date
Sep 14, 2015
Maturity date
Mar 1, 2026
Outstanding amount
‪2.75 B‬USD
Face value
1,000.00USD
Minimum denomination
2,000.00USD
Coupon
3.65% (Fixed)
Yield to maturity
4.67%
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Go deeper with bond data
Access the most important data for bonds including coupon rates, issue ratings, redemption data and more.